2024 universal registration document

1. Presentation of the Group – Integrated Report

1.4.1.4 Significant events and post-closing events
Strategy
  • Following the successful collaboration with the Prada brand, L’Oréal Groupe and Prada S.p.A announced in February a worldwide long-term license agreement for the creation, development, and distribution of the luxury beauty products for the Miu Miu brand, that is now joining the L’Oréal Luxe Division. The first fragrances under L’Oréal Groupe are expected to be launched in 2025.
  • In June, Nicolas Hieronimus, L'Oréal's CEO, gave a keynote speech at The Consumer Goods Forum in Chicago, demonstrating how L’Oréal is "Revolutionising Beauty with Technology." Consumer Products Division President Alexis Perakis-Valat joined a panel to deep dive into how L’Oréal creates a circular economy for plastics.
  • In August, L’Oréal announced the acquisition of a 10% stake in Galderma, for a non-disclosed amount. L’Oréal and Galderma have agreed to work towards a strategic scientific partnership that will leverage the expertise of both companies: Galderma’s across a broad range of dermatological solutions, and L’Oréal’s in skin biology, diagnostic tools and evaluation methods.
  • L’Oréal has acquired a minority stake in the High Perfumery House Amouage, becoming a long-term minority investor. Founded in Oman in 1983, to be ‘The Gift of Kings’, Amouage has redefined the Arabian art of perfumery, garnering a global reputation for bringing innovative modernity and true artistry to all its creations, today present in the world’s finest luxury sales points. Following the transaction, SABCO LLC remains Amouage’s majority shareholder.
  • In December, L’Oréal announced the signing of Gowoonsesang Cosmetics, owner of the Korean skincare brand Dr.G, from Swiss retail group Migros. Dr.G will be part of the Consumer Products Division, positioned to meet the rising demand for K-Beauty.
  • In February 2025, L’Oréal agreed to sell approximately 29.6 million of Sanofi shares to Sanofi for €101.5 per share, for a total consideration of €3 billion. Upon completion of the transaction and cancellation of the repurchased shares, L’Oréal will own 7.2% of Sanofi’s share capital and 13.1% of its voting rights.
  • In February 2025, L’Oréal announced a long-term, exclusive beauty partnership with Jacquemus, solidified by a minority investment supporting their independent development.
Research, Beauty Tech and Digital
  • In March, L’Oréal announced the launch of MelasylTM, a breakthrough molecule designed to address localised pigmentation issues. L’Oréal’s formulations containing this proprietary ingredient work inclusively, across all skin tones, to address pigmented marks on the skin and improve their appearance. Melasyl is the result of rigorous tests involving more than 120 scientific studies.
  • In February, Asmita Dubey, Chief Digital and Marketing Officer of L’Oréal was named the World Federation of Advertisers Global Marketer of the Year for 2023.
  • L’Oréal Advanced Research and the University of Oregon pioneered the first successful development of a bioprinted skin model mimicking natural human skin. Resulting from the L’Oréal Skin Technology Platform, this model enables the rapid and precise construction of skin-like structures. This reinforced the Group’s commitment to innovation and to Beauty with no animal testing.
  • At Viva Technology in Paris, L’Oréal unveiled a number of Beauty Tech innovations: Skin Technology, facial treatmentRenergie Nano-Surfacer|400 Booster (Lancôme) , skin diagnosis toolDerma-Reader (Kiehl’s) , hair health analyserMy Hair [iD] - Hair Reader (L’Oréal Professionnel) , personal beauty assistantBeauty Genius (L’Oréal Paris) andCREAITECH, theGen AI Beauty Content Lab.
  • In June, the Cannes Lions International Festival of Creativity 2024 awardedCeraVe the GRAND PRIX for Social & Influencer Marketing, alongside nine other Cannes Lions Awards, makingCeraVe one of the top-10 most awarded brands at the event.
  • In September, L’Oréal announced a tri-party agreement with Abolis Biotechnologies andEvonik, to enable discovery, development, and manufacturing of innovative and sustainable beauty ingredients.
  • During the Skin Alliance Forum in October, the Dermatological Beauty Division and the International League of Dermatological Societies (ILDS) announced a landmark study to research the availability and accessibility of dermatological services in 194 countries.
  • In October, L’Oréal earned the prestigious Applied Research Award at the 2024 IFSCC (International Federation of Societies of Cosmetic Chemists) Congress for the discovery of the skin-enhancing effects of ultramarine blue pigments in cosmetics.
  • At CES 2025 in Las Vegas, L’Oréal unveiled Cell BioPrint, a tabletop hardware device that provides personalised skin analysis in just five minutes, using advanced proteomics - the study of how protein composition in the human body affects skin aging.
  • In January 2025, IBM and L’Oréal announced a collaboration to leverage IBM’s GenAI technology and expertise to uncover new insights in cosmetic formulation data. This unique effort will develop a custom AI foundation model engineered to extend the speed and scale of L’Oréal’s innovation and reformulation pipeline, with products always reaching higher standards of inclusivity, sustainability, and personalization.